This federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Novartis Pharmaceuticals Corporation, a foreign-owned, for-profit manufacturer of pharmaceutical goods. The BPA, valued at $21.5 million, is for the procurement of Kymriah, a specialized cell therapy cancer treatment. Kymriah is a chimeric antigen receptor T-cell (CAR-T) therapy provided by Novartis under the company's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB), which has a ceiling value of $5.4 billion and runs through August 2026. The BPA supports the delivery of Kymriah to various VA Integrated Service Networks (VISNs) and medical centers to treat veterans. The contract does not have any set-aside designations. To date, Novartis has received over $2.8 million in Kymriah orders from the VA through this BPA and other contract vehicles.
The VA National Acquisition Center has issued multiple task orders under the BPA, ranging from $283,526.57 to $283,555.92, for the delivery of Kymriah to VA facilities in New Jersey, Florida, and other locations. These BPA call orders are firm-fixed-price contracts awarded under Novartis' FSS contract. The contracted services aim to provide specialized cancer therapy treatments to support the VA's healthcare programs for veterans through the procurement of Kymriah, a key pharmaceutical product in Novartis' portfolio of advanced medical treatments.